Compare Globus Medical Inc. Class A Common Stock (GMED) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs MPLX LP — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while MPLX LP trades at $57.5 (market cap $57.70B). The key difference: MPLX LP is far larger — about 5.6× Globus Medical Inc. Class A Common Stock's market cap, and MPLX LP pays a 7.57% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| GMED | MPLX | |
|---|---|---|
Market Cap | $10.25B | $57.70B |
Volume | 1,108,124 | 561,167 |
Sector | Health | Energy |
52-Week High | $96.82 | $60.51 |
52-Week Low | $58.33 | $48.53 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $9.76B | $82.80B |
Dividend Yield | — | 7.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
MPLX trades at $56.91, up 0.14% with a bearish technical signal despite strong fundamentals. The company reported $11.47B revenue and $4.91B net income for 2025, with robust profitability margins (40.45% net margin, 33.95% ROE). Recent earnings show mixed results with Q4 2025 beat but Q1 and Q2 2026 misses. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 12% upside potential.
The investment case balances strong cash flow generation and dividend yield against energy market volatility risks. MPLX's fee-based midstream model provides revenue stability, but recent technical weakness and earnings misses warrant caution. The stock offers value with a 12.24 P/E ratio and dividend income potential, though investors should monitor Q3 2026 earnings due November 3rd for confirmation of business momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
